17.54 USD
+0.92 (+5.54%)
17.54 USD
0 (0%)
FTRE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. FTRE may be in some trouble as it scores bad on both profitability and health. FTRE has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
FTRE had positive earnings in the past year.
In the past year FTRE had a positive cash flow from operations.
In multiple years FTRE reported negative net income over the last 5 years.
FTRE had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -37.01%, FTRE is not doing good in the industry: 78.95% of the companies in the same industry are doing better.
FTRE has a worse Return On Equity (-174.74%) than 85.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.01% | ||
| ROE | -174.74% | ||
| ROIC | N/A |
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 18.61%, FTRE is doing worse than 84.21% of the companies in the same industry.
In the last couple of years the Gross Margin of FTRE has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for FTRE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
2. Health
2.1 Basic Checks
FTRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FTRE has more shares outstanding
The debt/assets ratio for FTRE has been reduced compared to a year ago.
2.2 Solvency
FTRE has an Altman-Z score of 0.69. This is a bad value and indicates that FTRE is not financially healthy and even has some risk of bankruptcy.
FTRE has a worse Altman-Z score (0.69) than 68.42% of its industry peers.
A Debt/Equity ratio of 1.81 is on the high side and indicates that FTRE has dependencies on debt financing.
FTRE has a worse Debt to Equity ratio (1.81) than 84.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.81 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.69 |
ROIC/WACCN/A
WACC11.25%
2.3 Liquidity
FTRE has a Current Ratio of 1.00. This is a normal value and indicates that FTRE is financially healthy and should not expect problems in meeting its short term obligations.
FTRE has a Current ratio of 1.00. This is amonst the worse of the industry: FTRE underperforms 87.72% of its industry peers.
FTRE has a Quick Ratio of 1.00. This is a normal value and indicates that FTRE is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.00, FTRE is doing worse than 80.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1 | ||
| Quick Ratio | 1 |
3. Growth
3.1 Past
FTRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.71%, which is quite impressive.
Looking at the last year, FTRE shows a decrease in Revenue. The Revenue has decreased by -0.54% in the last year.
The Revenue has been decreasing by -4.10% on average over the past years.
EPS 1Y (TTM)45.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.83%
Revenue 1Y (TTM)-0.54%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%3.91%
3.2 Future
Based on estimates for the next years, FTRE will show a very strong growth in Earnings Per Share. The EPS will grow by 32.18% on average per year.
The Revenue is expected to grow by 2.57% on average over the next years.
EPS Next Y63.5%
EPS Next 2Y54.25%
EPS Next 3Y47.59%
EPS Next 5Y32.18%
Revenue Next Year0.87%
Revenue Next 2Y0.49%
Revenue Next 3Y1.32%
Revenue Next 5Y2.57%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 34.39, the valuation of FTRE can be described as expensive.
64.91% of the companies in the same industry are more expensive than FTRE, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.17, FTRE is valued a bit more expensive.
Based on the Price/Forward Earnings ratio of 21.68, the valuation of FTRE can be described as rather expensive.
FTRE's Price/Forward Earnings ratio is rather cheap when compared to the industry. FTRE is cheaper than 85.96% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.79, FTRE is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.39 | ||
| Fwd PE | 21.68 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of FTRE is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 216.2 |
4.3 Compensation for Growth
FTRE's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FTRE's earnings are expected to grow with 47.59% in the coming years.
PEG (NY)0.54
PEG (5Y)N/A
EPS Next 2Y54.25%
EPS Next 3Y47.59%
5. Dividend
5.1 Amount
No dividends for FTRE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
17.54
+0.92 (+5.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.28%
Inst Owner Change0%
Ins Owners0.34%
Ins Owner Change21.45%
Market Cap1.62B
Revenue(TTM)2.76B
Net Income(TTM)-1.01B
Analysts53.75
Price Target13.36 (-23.83%)
Short Float %11.3%
Short Ratio7.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)88.02%
Min EPS beat(2)-21.52%
Max EPS beat(2)197.56%
EPS beat(4)2
Avg EPS beat(4)62.76%
Min EPS beat(4)-51.68%
Max EPS beat(4)197.56%
EPS beat(8)2
Avg EPS beat(8)-65.55%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.39%
Min Revenue beat(2)6.15%
Max Revenue beat(2)10.63%
Revenue beat(4)3
Avg Revenue beat(4)4.73%
Min Revenue beat(4)-2.83%
Max Revenue beat(4)10.63%
Revenue beat(8)3
Avg Revenue beat(8)-0.6%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)26.57%
PT rev (3m)71.24%
EPS NQ rev (1m)0.19%
EPS NQ rev (3m)-8.77%
EPS NY rev (1m)0.08%
EPS NY rev (3m)-1.57%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.77%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.39 | ||
| Fwd PE | 21.68 | ||
| P/S | 0.59 | ||
| P/FCF | N/A | ||
| P/OCF | 1080.46 | ||
| P/B | 2.79 | ||
| P/tB | N/A | ||
| EV/EBITDA | 216.2 |
EPS(TTM)0.51
EY2.91%
EPS(NY)0.81
Fwd EY4.61%
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)0.02
OCFY0.09%
SpS29.87
BVpS6.29
TBVpS-10.96
PEG (NY)0.54
PEG (5Y)N/A
Graham Number8.49
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.01% | ||
| ROE | -174.74% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.61% | ||
| FCFM | N/A |
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
F-Score4
Asset Turnover1.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.81 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 86.95 | ||
| Cap/Depr | 18.24% | ||
| Cap/Sales | 0.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 12.4% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1 | ||
| Quick Ratio | 1 | ||
| Altman-Z | 0.69 |
F-Score4
WACC11.25%
ROIC/WACCN/A
Cap/Depr(3y)43.05%
Cap/Depr(5y)33.05%
Cap/Sales(3y)1.37%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.83%
EPS Next Y63.5%
EPS Next 2Y54.25%
EPS Next 3Y47.59%
EPS Next 5Y32.18%
Revenue 1Y (TTM)-0.54%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%3.91%
Revenue Next Year0.87%
Revenue Next 2Y0.49%
Revenue Next 3Y1.32%
Revenue Next 5Y2.57%
EBIT growth 1Y22.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.49%
EBIT Next 3Y9.63%
EBIT Next 5Y10.01%
FCF growth 1Y85.25%
FCF growth 3Y18.31%
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3Y15.67%
OCF growth 5YN/A
FORTREA HOLDINGS INC / FTRE FAQ
What is the ChartMill fundamental rating of FORTREA HOLDINGS INC (FTRE) stock?
ChartMill assigns a fundamental rating of 2 / 10 to FTRE.
What is the valuation status for FTRE stock?
ChartMill assigns a valuation rating of 4 / 10 to FORTREA HOLDINGS INC (FTRE). This can be considered as Fairly Valued.
Can you provide the profitability details for FORTREA HOLDINGS INC?
FORTREA HOLDINGS INC (FTRE) has a profitability rating of 2 / 10.
Can you provide the financial health for FTRE stock?
The financial health rating of FORTREA HOLDINGS INC (FTRE) is 1 / 10.